2025 Annual Meeting | Industry Therapeutic Update from Octapharma: Broadening Horizons in Autoimmune Diseases Immunoglobulin Therapy in an Evolving Landscape

Date Monday 04/07/25

Time 06:00 PM - 08:00 PM PDT Add To Calendar

Location Marriott Marquis | San Diego C

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) David R. Cornblath, MD, Suraj Muley, MD, FAAN, Namita Goyal, MD, FAAN

Topic(s) General Neurology, Autoimmune Neurology

Learning Objectives Join Octapharma in this dinner program at the Marriott Marquis San Diego Ballroom C.
Welcome and Introduction: Chair: David R. Cornblath, M.D., John Hopkins University, MD
A Roadmap for CIDP Care: Reviewing Treatment Strategies: David R. Cornblath, M.D., John Hopkins University, MD
Decoding IVIg: How Multi-Pathway Mechanisms Drive Extensive Immune Modulation: Suraj A. Muley, M.D., University of Arizona, AZ
Exploring Frontiers in Dermatomyositis: Namita A. Goyal, M.D., University of California, Irvine, CA
Q&A: All Faculty
Closing Remarks: David R. Cornblath, M.D., John Hopkins University, MD
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2025 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
06:00 PM - 08:00 PM PDT	Speaker	Industry Therapeutic Update from Octapharma: Broadening Horizons in Autoimmune Diseases Immunoglobulin Therapy in an Evolving Landscape

Faculty Disclosures
David R. Cornblath, MD	Dr. Cornblath has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Octapharma. Dr. Cornblath has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Annexon. Dr. Cornblath has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Pfizer. Dr. Cornblath has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Grifols. Dr. Cornblath has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cigna. Dr. Cornblath has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Cornblath has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Anavex. Dr. Cornblath has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hansa. Dr. Cornblath has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MPTP. Dr. Cornblath has received intellectual property interests from a discovery or technology relating to health care.
Suraj Muley, MD, FAAN	Dr. Muley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Muley has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Muley has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for CSL Behring. Dr. Muley has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Dr. Muley has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Catalyst. Dr. Muley has received publishing royalties from a publication relating to health care.
Namita Goyal, MD, FAAN	Dr. Goyal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Goyal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Annexon. Dr. Goyal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Goyal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Fulcrum. Dr. Goyal has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for CSL Behring. Dr. Goyal has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Argenx. The institution of Dr. Goyal has received research support from Fulcrum. The institution of Dr. Goyal has received research support from Annexon. The institution of Dr. Goyal has received research support from Healey Platform. The institution of Dr. Goyal has received research support from Medicinova. The institution of Dr. Goyal has received research support from Transposon. The institution of Dr. Goyal has received research support from Abcuro. The institution of Dr. Goyal has received research support from Calico. The institution of Dr. Goyal has received research support from Clene. The institution of Dr. Goyal has received research support from Janssen. The institution of Dr. Goyal has received research support from PepGen. The institution of Dr. Goyal has received research support from PTC. The institution of Dr. Goyal has received research support from Roche. The institution of Dr. Goyal has received research support from Sanofi. Dr. Goyal has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��